Tracers / [225Ac]Ac-Macropa-7065
[225Ac]Ac-Macropa-7065
Also written as [Ac-225]Macropa-7065
- Radionuclide
- Ac-225 t½ 14284.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 1
What it is
- Compound class
- Antibody-chelator conjugate (radioimmunoconjugate, Macropa-PEG4 chelator on anti-aITGB2 antibody clone 7065)
- Target / mechanism
- Active conformation of integrin-β2 (aITGB2), a tumor-selective epitope on AML cells, targeted by conformation-specific antibody clone 7065 PMID 41282197
- Clinical application
- Radioimmunotherapy for Acute Myeloid Leukemia targeting aITGB2, evaluated preclinically in AML models with potential for future clinical translation PMID 41282197
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | 55 ± 1.76 % | >98% | Macropa-PEG4-7065 | 41282197 2025 Res Sq An aliquot of 4 μL (approx. 1.11 MBq of Ac-225) was added to a vial followed by 50 μL of NH4OAc (2M, pH 5.8) and 20 μL of L-Ascorbic acid (150 mg/mL) and 120 μg of Macropa-PEG4-7065 (7.6 μL). — [225Ac]Macropa-PEG4-7065 and [225Ac]Macropa-PEG4-IgG were obtained with a radiochemical yield of 55 ± 1.76 % and 65 ± 0.06 % yield (n=4 syntheses each) with radiochemical purity exceeding 98% |
Need this precursor?We can point you to suppliers for [225Ac]Ac-Macropa-7065, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41282197: 'Macropa-PEG4-7065 and Macropa-PEG4-IgG were obtained with antibody-to-chelator ratios of 1.61 and 0.43'. | Stage 28: added indication(s) onc-leukemia from consolidated missing-rubric review.